Comparing ibrutinib efficacy and toxicity levels by age for patients with CLL/SLL
Factors to consider when choosing treatment for relapsed multiple myeloma patients
COMy 2017: Day 2 discussion on relapsed myeloma, treatment, plasma cell leukemia and awards
Arnon Nagler et al.
Results of KEYNOTE-023 and pembrolizumab plus pomalidomide trials for multiple myeloma
Jesús San Miguel
Current research in the field of multiple myeloma